Application of medical adhesive inhibits intimal hyperplasia involving the downregulation of ERK1/2 and eNOS levels

SHOUDONG CHAI$^{1,2}$, YANG YU$^1$, HAIMING LI$^1$, MINGXIN GAO$^1$, BO LI$^1$ and CHENGXIONG GU$^1$

$^1$Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing 100029; $^2$Department of Cardiac Surgery, Liaocheng People's Hospital, Clinical School of Taishan Medical University, Liaocheng, Shandong 252000, P.R. China

Received July 10, 2017; Accepted September 18, 2017

DO: 10.3892/mmr.2018.9492

Abstract. Vein graft remains the most broadly applied vascular material in coronary artery bypass surgery. However, the restenosis rate of the vein bridge following angioplasty is high. The present study investigated the effect of medical adhesive on vascular intimal hyperplasia, in addition to the signal transduction mechanism. A total of 36 New Zealand white rabbits were divided into three groups at random, including the normal group, the surgery group and the medical adhesive spray group. Following surgery for transplantation of the left external jugular vein to the ipsilateral common carotid artery for 4 weeks, the thickness and area of the intima and media of the vessel were measured on formalin-fixed, paraffin wax-embedded pathological sections using hematoxylin-eosin staining, and alterations in the expression of proliferating cell nuclear antigen (PCNA), platelet endothelial cell adhesion molecule 1 (PECAM-1), vascular cell adhesion protein 1 (VCAM-1), extracellular signal-regulated kinase (ERK)1/2, and endothelial nitric oxide synthase (eNOS) were detected by immunohistochemical staining, reverse transcription-quantitative polymerase chain reaction analysis and western blotting. The levels of intimal hyperplasia in the medical adhesive spray group were markedly decreased compared with the surgery group. Consistently, PCNA, PECAM-1 and VCAM-1 were underexpressed in the medical adhesive spray group compared with the surgery group. ERK1/2 and eNOS were underexpressed in the medical adhesive spray group compared with the surgery group. Therefore, the application of medical adhesive may inhibit intimal hyperplasia, which may be associated with the restriction of the over-distension of the vein graft by downregulating the ERK1/2 and eNOS levels, reducing injury to the vascular intima and inhibiting the signaling pathway involved in intimal hyperplasia.

Introduction

Due to its easy access and sufficient length, the great saphenous vein remains widely used in coronary artery bypass surgery (1,2). However, the long-term effect of the vein graft is restricted by its decreased patency rate. The present study focused on the effect and molecular mechanism of medical cyanoacrylate glue on the long-term patency of rabbit vein grafts.

When vein grafts are transplanted into the arterial system, dilatation occurs under arterial pressure, which causes the vascular wall to stretch, triggering remodeling of the vascular wall. Once the vein bridge in the blood vessel dilates, the diameter of the artery and vein blood vessel is increased, which causes a further mismatch in the arteriovenous anastomosis. In addition, blood flow is disordered in the anastomosis and the venous vascular segment. When laminar blood flows through the blood vessels, the flow has a protective effect on the inner wall of the blood vessels. In disease, the abnormal and disordered blood flow leads to vascular endothelial cell damage and dysfunction (3-5). Mechanotransduction is involved in the cytokine release of sensitive cells and signaling activation by mechanical stress (6,7). The activated signaling pathway is transformed into a cellular chemical signaling, and eventually regulates the cellular functioning of the effector cells by altering gene and protein expression levels (8-10).

Platelet endothelial cell adhesion molecule 1 (PECAM-1) is a type of mechanosensor, which serves important roles in promoting the release and delivery of biological signals via the signaling pathways with which it interacts (11). Proliferating cell nuclear antigen (PCNA) is a marker for the assessment of cell proliferation (12,13). It was demonstrated that vascular cell adhesion protein 1 (VCAM-1), ERK1/2 and endothelial nitric oxide synthase (eNOS) expression has important roles in injured arteries (14-16). In the present study, 36 New Zealand white rabbits were divided into three groups at random, with 12 in each group: The first group received no surgery (normal group); one group was subjected to transplantation of the left external jugular vein to the ipsilateral common carotid artery (surgery group); the other was subjected to transplantation of left external jugular vein to the common carotid artery on the labial side followed by the application of medical adhesive spray (medical adhesive

Key words: medical adhesive, intimal proliferation, vein graft

Correspondence to: Dr Chengxiong Gu, Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Diseases, 2 Anzhen Road, Beijing 100029, P.R. China

E-mail: cr7236@163.com

MOLECULAR MEDICINE REPORTS 18: 4643-4649, 2018
spray group). A total of 4 weeks post-surgery, vascular ultrasound was performed to measure blood vessel diameter and vessel blood flow velocity. For pathological examination, the vein graft was removed, the thickness and area of the intima and media of the vessel were measured based via images, and alterations in the expression of PCNA, PECAM-1, VCAM-1, extracellular signal-regulated kinase (ERK)1/2 and eNOS were detected by immunohistochemical staining, reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis and western blotting.

**Materials and methods**

**Animals.** A total of 36 New Zealand white rabbits were randomly selected and divided into three groups, 12 rabbits/group. Rabbits were provided by Capital Medical University (Beijing, China). Of the three groups, one received no surgery (normal group), one received transplantation of the left external jugular vein to the ipsilateral common carotid artery (surgery group), and the other received the transplantation of the left external jugular vein to the common carotid artery on the labial side followed by medical adhesive spray (medical adhesive spray group) (Fig. 1). Animals were maintained at 22°C with 55% humidity on a standard 12 h light/dark cycle with food and water available ad libitum. Animal experiments were in accordance with the ethics standards of animal research. The present study was approved by the Animal Experiments and Experimental Animal Welfare Committee of Capital Medical University (approval no. AEEI-2015-144).

**Establishment of the model of rabbit external jugular vein graft in the common carotid artery.** The autologous vein graft model was established. The rabbits were treated with fasting and water for 4 h prior to the surgery, the ear edge vein channel was established, and 30 g/l amobarbital anesthesia was administered intravenously with 30 mg/kg concentration. Subsequently, rabbits were fixed in a supine position. Longitudinal incisions were made from the anterior median of the neck skin and 30-50 mm of the jugular vein was cut, washed and soaked in heparin saline. The right common carotid artery was dissociated, and an ear margin vein injection of 10 g/l heparin (1 ml/kg) as given. Carotid artery catheterization was performed and a Philips V24E monitor (Philips Medical Systems, Inc., Bothell, WA, USA) was used to monitor the mean arterial blood pressure. Following occlusion of the proximal and distal resection of the carotid artery, the appropriate vein length was cut and inverted. An 8-0 nylon monofilament line was used for end-to-end anastomosis with an 8-10 needle, followed by opening the ends of the artery clamps to exhaust. Once the patency of the vein bridge and a lack of bleeding was ensured, the suture incision was performed layer by layer. An ear margin vein injection of 10 g/l heparin (1 ml/kg) was subsequently administered to prevent thrombosis, and an injection of penicillin (800,000 units) was administered to prevent infection. On the same day as the surgery, or the following day, blood vessel specimens were examined using the Philips IU22 color Doppler ultrasonic detector (Philips Medical Systems, Inc.) to ensure the patency of the vein bridge. Images of blood flow were acquired via postoperative ultrasonic measurement. The rabbits were constantly fed for 4 weeks. Daily observations of the animals were made and the data recorded.

**Specimen collection and immunohistochemical detection.** Immunohistochemical examination, RT-qPCR analysis and western blotting were used to detect the expression of PCNA, PECAM-1, VCAM-1, ERK1/2 and eNOS in the vein bridge. A total of 4 weeks subsequent to surgery, 30 g/l amobarbital anesthesia was used to treat the animals. Following anesthesia, the average arterial pressure was detected via left carotid artery catheterization. The right vein graft was separated and the required graft tissue was rapidly cut. The external jugular vein graft bridges of the three groups of rabbits were fixed in 4% polyformaldehyde at 4°C for 1 h. Following dehydration and permeabilization with 0.01% Triton X-100, the sections were embedded in paraffin. The thickness was 4 µm. Following embedding in paraffin, sections were blocked with 1% bovine serum albumin (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) at 20°C for 1 h and stained with hematoxylin-eosin at room temperature for 4 h. Sections were subsequently incubated with primary antibodies against PCNA (1:100; cat. no. ab29; Abcam), PECAM-1 (1:100; cat. no. ab28364; Abcam), VCAM-1 (1:100; cat. no. ab106777; Abcam), ERK1/2 (1:100; cat. no. ab196883; Abcam) at 20°C for 2 h, followed by incubation with horseradish peroxidase-conjugated goat anti-rabbit and anti-mouse secondary antibodies (1:500; cat. nos. S004 and S001, respectively; Beijing TDI Biotech Co., Ltd., Beijing, China) at room temperature for 1 h. Sections were sealed and observed by light microscopy at a magnification of x100. Image analysis was performed using an Olympus BX50 microscope (Olympus Corporation, Tokyo, Japan). The microscope was used to observe the tissue sections, and Image Pro Plus software 6.0 (Media Cybernetics, Inc., Rockville, MD, USA) was used to perform image acquisition and image analysis. The alterations in average arterial pressure prior to and following surgery, and the thickness and area of the graft vein intima and media were detected.

The RT-qPCR analysis and western blotting were performed by previously described methods (9,17). The specific primer sequences for each gene, including the reference gene were (5'-3'): PCNA forward, GGAAGTCAGTAGTGAAGACGTCCTGG and reverse, TTCTCCACTGGCGGAAACACTT; PECAM-1 forward, AACATGCGATGACGGCGAT and reverse, ACCGAGACATTCACDCTCTG; ERK1/2 forward, ATAAAGACCAAGGCAGCT and reverse, CAGCCAACGCAAATCCA; eNOS forward, CACCCAGCA ACTTACCCAG and reverse, AGGGCAAGGCAGTTC and β-actin forward, AAGTGCACATGGAAGACG and reverse, GGCGGGGTATGTCCTCTG. For western blot analysis, primary antibodies against PCNA (1:500; cat. no. ab29; Abcam), PECAM-1 (1:500; cat. no. ab28364; Abcam), VCAM-1 (1:500; cat. no. ab106777; Abcam), ERK1/2 (1:500; cat. no. ab196883; Abcam), eNOS (1:500; cat. no. YM3164; ImmunoWay Biotechnology Company, Plano, TX, USA) and β-actin (1:1000; cat. no. ab8227; Abcam) were incubated with the blots overnight at 4°C, followed by incubation with horseradish peroxidase-conjugated goat anti-rabbit and anti-mouse secondary antibodies (1:500; cat. nos. S004 and S001, respectively; Beijing TDI Biotech Co., Ltd., Beijing, China) at room temperature for 1 h. Sections were sealed and observed by light microscopy at a magnification of x100.
anti-rabbit and anti-mouse secondary antibodies (1:1,000; cat. nos. S004 and S001, respectively; Beijing TDY Biotech Co., Ltd.) at room temperature for 1 h.

Statistical analysis. SPSS 21.0 statistical analysis software (IBM Corp., Armonk, NY, USA) was applied, using the Student’s t-test for two independent groups or one-way analysis of variance followed by Tukey’s post-hoc test. All data are expressed as mean ± standard deviation. P<0.05 was considered to indicate a statistically significant difference.

Results

Pathological examination of vein grafts. The results of the present study demonstrated that the graft vascular wall was thickened in the surgery group, although this was not apparent in the normal and medical adhesive spray groups, illustrating that medical adhesive spray led to a positive outcome in the patency of the rabbit vein graft (Fig. 2).

A total of 4 weeks post-surgery, the thickness and area of the intima and media of vessel were measured on
Figure 3. Expression of PCNA in vascular tissues. Rabbits were randomly divided into three groups: Normal group, lanes C1 and C2; rabbit external jugular vein graft in the common carotid artery (surgery group, lanes O1 and O2), and rabbit external jugular vein graft with medical adhesive spray in the common carotid artery (medical adhesive spray, lanes M1 and M2). (A) Immunohistochemistry staining. (B) mRNA expression analysis using the reverse transcription-quantitative polymerase chain reaction. (C) Protein expression analysis using western blotting. **P<0.01 vs. normal. PCNA, proliferating cell nuclear antigen.

Figure 4. Expression of PECAM-1 and VCAM-1 in vascular tissues. Rabbits were randomly divided into three groups: Normal group, lanes C1 and C2; rabbit external jugular vein graft in the common carotid artery (surgery group, lanes O1 and O2), and rabbit external jugular vein graft with medical adhesive spray in the common carotid artery (medical adhesive spray, lanes M1 and M2). (A) Immunohistochemistry staining. (B) mRNA expression analysis using the reverse transcription-quantitative polymerase chain reaction. (C) Protein expression analysis using western blotting. **P<0.01 vs. normal; ***P<0.01 vs. surgery. PECAM-1, platelet endothelial cell adhesion molecule 1; VCAM-1, vascular cell adhesion protein 1.
formalin-fixed, paraffin-wax-embedded pathological sections (Table I). Based on hematoxylin-eosin staining, it was observed that the graft intima was markedly thickened in the normal group (Table I). The lumen was narrowed, with the appearance of a large number of proliferated smooth muscle cells under the intima. The smooth muscle cells were in a disordered arrangement, presenting as the typical phenotype of secretory cells. Collagen fibers around the cell membrane were slightly thickened.

In the medical adhesive spray group, the intimal thickening was weakened compared with that in the normal group. The intima was notably small compared with the normal group. There was no obvious thickening of the media (Table I).

The intimal thicknesses of the normal group and the medical adhesive spray group were 107.50±12.73 and 41.34±14.53 µm (P<0.01), respectively. Intimal areas were 1.031±0.043 and 0.533±0.022 mm² (P<0.01), respectively. The thicknesses of the media of the vein graft in the normal group and the medical adhesive spray group were 115.04±15.42 and 103.38±11.13 mm (P>0.05), respectively. The areas of the media were 1.092±0.051 and 1.054±0.030 mm² (P>0.05), respectively.

Medical adhesive spray inhibits the injury-induced expression of PCNA. In order to examine the proliferation characteristics of vascular intimal tissues, immunohistochemical staining...
was performed using the monoclonal antibody of PCNA to test the level of PCNA in vascular wall tissues.

It was observed that yellow-brown particles in the vascular endothelial cell nuclei were positive for PCNA staining (Fig. 3). The expression of PCNA was significantly increased in the surgery group compared with the normal and medical adhesive spray groups (P<0.01).

**Medical adhesive spray inhibits the injury-induced expression of PECAM-1 and VCAM-1.** PECAM-1 was primarily located at the connection between endothelial cells, and was stained dark brown (Fig. 4A). PECAM-1 and VCAM-1 were more highly expressed in the surgery groups compared with the normal group (P<0.01). However, the use of medical adhesive inhibited the increase in PECAM-1 and VCAM-1.

**Medical adhesive spray inhibits the injury-induced expression of ERK1/2.** The expression of ERK1/2 was additionally detected (Fig. 5). Similar to the expression of PECAM-1 and VCAM-1, ERK1/2 was more highly expressed in the surgery groups compared with the normal group (P<0.01). However, the use of medical adhesive inhibited the increase in ERK1/2.

**Medical adhesive spray inhibits the injury-induced expression of eNOS.** The expression of eNOS was additionally detected (Fig. 6). Similar to the expression of ERK1/2, eNOS was more highly expressed in the surgery groups compared with the normal group (P<0.01). However, the use of medical adhesive inhibited the increase in eNOS.

**Discussion**

The excessive proliferation of smooth muscle cells and migration toward the intima, in addition to the abnormal deposition of vascular wall interstitial cells, results in vascular remodeling, vascular wall thickening, atherosclerosis and stenosis of the lumen (6,7). This process has been defined as vein arterIALIZATION (3-5). The present study demonstrated that the thickening of the venous wall was primarily caused by the proliferation of smooth muscle, which occurred over 4 weeks. Following transplantation of the vascular graft into the arterial environment, the vascular expansion resulted in an increased mechanical force (mechanical expansion and traction) with increased arterial pressure, causing damage to endothelial cells and smooth muscle cells, and triggering the release of various growth factors.

PCNA is an acidic polypeptide only synthesized and expressed in proliferating cells, and is additionally termed cyclin. As the auxiliary protein of DNA polymerase δ, PCNA is an important factor during cell synthesis (18-20). The expression of PCNA has been demonstrated to be associated with cell proliferation, and it acts as an indicator of cell proliferation (19). The most important function of PCNA is that it acts as an auxiliary protein of DNA polymerase 6 during nucleic acid metabolism (21). PCNA is, therefore, essential for DNA synthesis. DNA synthesis is the key event of the cell proliferation cycle. PCNA is a cell proliferation marker antigen (22). In the cell cycle, the synthesis of PCNA is important for the entry of cells into the S phase from the G0 and G1 phases. PCNA expression has been demonstrated to be increased in the late stages of cell entry into the G1 phase, reaches its peak in the S phase, and decreases in the G2 and M phases (23). The results of the present study demonstrated that expression of PCNA was significantly increased in the surgery group compared with the normal and the medical adhesive spray groups, indicating that the medical adhesive inhibited cell proliferation following surgery.

The present study demonstrated that a stent may reduce tension injury to the vein graft wall in the arterial environment, prevent the continuous expansion of the vein graft at arterial pressure, and reduce mechanical damage to the vascular endothelial cells and smooth muscle cells. Medical adhesive has been further demonstrated to prevent the excessive expansion of vein grafts, accelerate the blood flow rate, and decrease leukocyte adhesion, fibrin deposition, and thrombus formation and platelet aggregation (3-5). It has been demonstrated that laminar shear stress inhibits the proliferation of endothelial cells through the induction of cell cycle dependent kinase inhibitors, although disordered fluid shear stress may remove this inhibition and consequently promote cell proliferation (24). ERK1/2 and eNOS are involved in the expansion of vascular wall (6,25). Medical adhesive spray may inhibit the expansion of the vascular wall via inhibition of the ERK1/2 and eNOS signaling pathways.

PECAM-1 and VCAM-1 are primarily distributed in blood cells and vascular endothelial cells. PECAM-1 and VCAM-1 are involved in the signal transduction of adhesion molecules, and may additionally regulate the function of endothelial cells (26,27). The cell-cell interactions between endothelial cells are the structural foundation for the maintenance of vascular integrity and the regulation of leukocyte infiltration, in addition to vascular permeability (28,29).

PECAM-1 belongs to a superfamily of immunoglobulin adhesion molecules. PECAM-1 is expressed in activated platelet membrane and vascular endothelial cells, and may induce the initial stages of inflammation and stimulate the migration of leukocytes by participating in the transition of extracellular signals to the intracellular environment (30). PECAM-1 is able to control the activity of platelets, regulate the migration of leukocytes to the vascular intima and maintain the integrity of the vessel wall. If endothelial cells are injured, their function is decreased, leading to adverse consequences (31,32). The results of the present study suggested that PECAM-1 and VCAM-1 may serve important roles in the regulation of endometrial hyperplasia by medical adhesive.

In conclusion, the application of medical adhesive significantly inhibited intimal hyperplasia, which may be associated with restriction of the over-distension of the vein graft by downregulating the ERK1/2 and eNOS levels, reducing the injury to the vascular intima and inhibiting the signaling pathways involved in intimal hyperplasia. However, the exact mechanism underlying the role of medical adhesive in the inhibition of intimal hyperplasia requires further investigation.

**Acknowledgements**

Not applicable.

**Funding**

No funding was received.
Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Author's contributions

SC and CG conceived and designed the experiments. SC, YY, HL, MG and LB performed the experiments. SC produced the manuscript. SC and YY conducted data analysis.

Ethics approval and consent to participate

The present study was approved by the Animal Experiments and Experimental Animal Welfare Committee of Capital Medical University (approval no. AEEI-2015-144).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References